Fragile X Syndrome

New insights into the long-lasting effects of Fragile X syndrome on connections in the brain during early development highlight the importance of early detection and treatment. Read More

Samuel Friedman, a senior from Plymouth, Ma., majoring in molecular and cellular biology, recently won a Victoria Finnerty Undergraduate Travel Award from the Genetics Society of America. The award allowed Friedman to present his research at the 54th Annual Drosophila Research Conference in Washington, D.C. Read More

Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners. Read More

Vanderbilt Kennedy Center (Vanderbilt University) The Vanderbilt Kennedy Center’s Fragile X Treatment Research Program will present information and current research on fragile X at a symposium titled “Transitions and Adulthood.” The free event is Monday, Aug. 20, at 6:30 p.m. at the Holiday Inn Nashville-Vanderbilt… Read More

The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders. Read More

Researchers at Vanderbilt University Medical Center have made substantial progress in developing potential new treatments for Parkinson’s disease, schizophrenia and fragile X syndrome, the most common genetic form of autism. Read More

Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism. Read More

Learn more about Fragile X syndrome and the advancements in research. Read More

Panelists will discuss how research findings are improving clinical care of this inherited disability. Read More

Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain. Read More